

Earnings Chat: Pharma, Tariffs, Fear & Loathing and Uncertainty
Jun 2, 2025
Dave and Andrew explore the earnings of McKesson and Crocs, diving into market positions and growth potential. They discuss the impact of changing pharmaceutical pricing policies and tariffs on these companies. The analysis highlights McKesson's financial health in pharmaceutical distribution and Crocs' consumer-centric approach. Insights from financial metrics and current market uncertainties are also shared, encouraging listeners to consider strategic investments while utilizing tools like FinChat for deeper research.
AI Snips
Chapters
Transcript
Episode notes
McKesson's Growth Amid Uncertainty
- McKesson leads pharmaceutical distribution with diverse growth drivers like GLP-1 drugs and prescription technology.
- Despite political uncertainty, strong fundamentals and acquisitions fuel accelerating revenues and profits.
Use Data Over Market Noise
- Dislocations between market narratives and company numbers can create investment opportunities.
- Use financial data to differentiate between market fear and true business health before making decisions.
GLP-1 Drugs Boost McKesson
- GLP-1 drugs are becoming a substantial revenue driver for McKesson, with 46% growth and nearly $50 billion annual run rate.
- This growth offsets some fears about pharmaceutical pricing uncertainties and strengthens McKesson's position.